Economic Burden of Hypercholesterolemia in the Russian Federation

被引:6
作者
Kontsevaya, Anna V. [1 ]
Balanova, Yulia A. [2 ]
Imaeva, Asia E. [3 ]
Khudyakov, Mihail B. [2 ]
Karpov, Oleg I. [4 ]
Drapkina, Oksana M. [5 ]
机构
[1] Natl Med Res Ctr Prevent Med, Sci & Analyt Work, Petroverigsky Per 10, Moscow 101990, Russia
[2] Natl Med Res Ctr Prevent Med, Lab Econ Anal Epidemiol Res & Prevent Technol, Dept Epidemiol Chron Noncommunicable Dis, Petroverigsky Per 10, Moscow 101990, Russia
[3] Natl Med Res Ctr Prevent Med, Dept Epidemiol Chron Noncommunicable Dis, Petroverigsky Per 10, Moscow 101990, Russia
[4] Publ Co Sanofi Russia, Hlth Econ & Outcomes Res Grp, Tverskaya Ul 22, Moscow 125009, Russia
[5] Natl Med Res Ctr Prevent Med, Petroverigsky Per 10, Moscow 101990, Russia
关键词
hypercholesterolemia; cardio-vascular diseases; economic burden; health care expenditures;
D O I
10.20996/1819-6446-2018-14-3-393-401
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background. The prevalence of hypercholesterolemia (HCE) is quite high in the Russian Federation (RF), and it is associated with clinical consequences and with potential economic impact. Impact includes not only cost of its correction, but also the cost of treatment of diseases and complications, as well as the deficiency of the gross domestic product (GDP). Aim. Evaluation of economic impact due to HCE in the Russian population, including direct expenditures of the Health Care System as well as nondirect impact in common economy. Material and methods. Prevalence of HCE in the RF was identified based on local published studies. Local statistical data (2016) on cardio-vascular diseases (CVDs), including Ischemic Heart Disease (IHD), Myocardial Infarction and cerebral-vascular disease were included in the analysis. Population Attributive Risk (PAR) of HCE in CVDs has been extrapolated on all Russian population. Official statistics, parameters of Govern Guarantees Program of Free Medical Aid were used for modelling of direct and non-direct components of economic impact. Total amount of premature deaths with calculation of years of potential life lost until life expectation at 72 years was calculated. Economic impact due to premature CVDs mortality in economic activity age with consideration on ratio of employment have included GDP lost. Calculation of GDP lost also included monetary impact based on number of disability CVDs patients multiplied on GDP per capita in disability group. Results. Visits to policlinics of patients with CVDs and HCE had a first place among all calls for medical aid. In the same time, hospitalization required in higher expenditures (outpatients cost treatment expenditures were 2.43 billion RUR, in-patients treatment -18.21 billion RUR). IHD with HCE was most expensive for direct expenditures in comparison with other CVD groups: more than 28.9 billion RUR per year, and with direct non-medical expenditures of 29.3 billion RUR in total. Years of potential life lost in economic active age were one million in total, 1.29 trillion RUR per year mostly due to indirect expenditures due to premature deaths in economy activity age (99% of impact). Total Economic impact due to HCE in the Russian population for all HCE are estimated as 1.295 trillion RUR. Conclusion. Total economic impact due to HCE in the RF is 1.5% of GDP (2016), 1.295 trillion RUR. Direct expenditures included Health Care System expenses; disability covering had 2.3% only. Main part of impact is economic lost due to premature mortality and decrease of labor productivity. HCE patients control at target levels with help of healthy lifestyle and adequate pharmaceutical therapy can decrease economic impact.
引用
收藏
页码:393 / 401
页数:9
相关论文
共 40 条
  • [1] Analysis of hypercholesterolemia prevalence in the outpatient practice (according to the ARGO study): Part I
    Akhmedzhanov, N. M.
    Nebieridze, D. V.
    Safaryan, A. S.
    Vygodin, V. A.
    Shuraev, A. Yu.
    Tkacheva, O. N.
    Lishuta, A. S.
    [J]. RATIONAL PHARMACOTHERAPY IN CARDIOLOGY, 2015, 11 (03) : 253 - 260
  • [2] [Anonymous], CARDIOVASC THER PREV
  • [3] [Anonymous], 2017, STAT B LABOR EMPLOYM
  • [4] Balanova Yu. A., 2005, RESULTS 1 STAGE EPID
  • [5] Global Overview of the Epidemiology of Atherosclerotic Cardiovascular Disease
    Barquera, Simon
    Pedroza-Tobias, Andrea
    Medina, Catalina
    Hernandez-Barrera, Lucia
    Bibbins-Domingo, Kirsten
    Lozano, Rafael
    Moran, Andrew E.
    [J]. ARCHIVES OF MEDICAL RESEARCH, 2015, 46 (05) : 328 - 338
  • [6] Cardiovascular morbidity associated with nonadherence to statin therapy
    Blackburn, DE
    Dobson, RT
    Blackburn, JL
    Wilson, TW
    [J]. PHARMACOTHERAPY, 2005, 25 (08): : 1035 - 1043
  • [7] Contribution of modern cardiovascular treatment and risk factor changes to the decline in coronary heart disease mortality in Scotland between 1975 and 1994
    Capewell, S
    Morrison, CE
    McMurray, JJ
    [J]. HEART, 1999, 81 (04) : 380 - 386
  • [8] Falling cholesterol trend at acute coronary syndrome presentation is strongly related to statin use for secondary prevention
    Chan, Thomas
    Dabin, Bilyana
    Hyun, Karice
    Ranasinghe, Isuru
    Neubeck, Lis
    Aliprandi-Costa, Bernadette
    Lefkovits, Jeffrey
    Devlin, Gerard
    Juergens, Craig
    Chew, Derek P.
    Brieger, David
    Ben Freedman, S.
    [J]. INTERNATIONAL JOURNAL OF CARDIOLOGY, 2016, 212 : 192 - 197
  • [9] Cost-effectiveness of the use of low- and high-potency statins in people at low cardiovascular risk
    Conly, Jon
    Clement, Fiona
    Tonelli, Marcello
    Hemmelgarn, Brenda
    Klarenbach, Scott
    Lloyd, Anita
    McAlister, Finlay A.
    Husereau, Don
    Wiebe, Natasha
    Mec, Flora Au
    Manns, Braden
    [J]. CANADIAN MEDICAL ASSOCIATION JOURNAL, 2011, 183 (16) : E1180 - E1188
  • [10] Relationship between Adherence Level to Statins, Clinical Issues and Health-Care Costs in Real-Life Clinical Setting
    Dragomir, Alice
    Cote, Robert
    White, Michel
    Lalonde, Lyne
    Blais, Lucie
    Berard, Anick
    Perreault, Sylvie
    [J]. VALUE IN HEALTH, 2010, 13 (01) : 87 - 94